Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough ...
Pharvaris, a biopharmaceutical company based in Zug, Switzerland, announced the acceptance of multiple abstracts for presentation at three significant upcoming congresses focusing on angioedema, ...
All titles, abstracts, photos and YouTube presentations will need your research mentor’s approval prior to submitting your abstract. The abstract will be open to public viewing. Submit your abstract ...
CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announced eleven abstracts accepted for presentation at the 2021 American Society of Clinical ...
Oral presentation of investigator-initiated Phase 2 study evaluating ZYNLONTA ® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with r/r follicular lymphoma Poster presentation ...
Professor Philip Molyneaux will give an oral presentation on the key efficacy and safety results from the Phase 2b CORAL trial of nalbuphine ER for the treatment of chronic cough in patients with ...
Pharvaris, a biopharmaceutical company based in Zug, Switzerland, announced that abstracts for multiple presentations have been accepted for the 2025 National Summit of the US Hereditary Angioedema ...
Arcus Biosciences Announces Nine Abstracts Accepted for Presentation at the SITC 2018 Annual Meeting
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that nine ...
Each student registering to present at the Summit may make ONLY ONE presentation during the daytime sessions: i.e., only one poster or talk or panel discussion or screening, etc. With up to 300 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results